The Hypothalamic Melanocortin System Stimulates the Hypothalamo-Pituitary-Adrenal Axis in vitro and in vivo in Male Rats

Abstract

α-Melanocyte-stimulating hormone (α-MSH) is an agonist, and agouti-related protein (Agrp) an endogenous antagonist at the melanocortin 3 and 4 receptors which are found in the central nervous system (CNS). We have examined the effect of α-MSH and Agrp on the hypothalamo-pituitary-adrenal (HPA) axis in vitro and in vivo in male rats. Intraparaventricular nuclear (iPVN) injection of [Nle⁴,D-Phe⁷]-α-MSH (NDP-MSH) (a long-acting α-MSH analogue) increased plasma adrenocorticotropic hormone (ACTH) (10 min post-injection: 25.0 ± 3.9 vs. saline 10.9 ± 2.0, p < 0.05) and plasma corticosterone (10 min post-injection: 174.1 ± 14.2 vs. saline 124.7 ± 16.3 ng/ml, p < 0.05). iPVN injection of Agrp(83–132) increased plasma ACTH (24.2 ± 4.0 vs. saline 10.1 ± 1.0 pg/ml, p < 0.01). The combination of NDP-MSH and Agrp(83–132) administered iPVN significantly increased plasma ACTH (10 min post-injection: 21.3 ± 3.8 vs. 10.9 ± 2.0, p < 0.05) and plasma corticosterone (10 min post-injection: 169.0 ± 15.1 vs. saline 124.7 ± 16.3 ng/ml, p < 0.05), but there was no additive effect. Hypothalamic explants treated with α-MSH (100 nM) resulted in a 159 ± 23% increase in corticotropin-releasing hormone (CRH) release (p < 0.01) and 175 ± 12% increase in arginine vasopressin (AVP) release (p < 0.001) compared to basal. Agrp(83–132) (100 nM) administered to hypothalamic explants resulted in a 161 ± 20% increase in CRH (p < 0.01) and 174 ± 13% increase in AVP release (p < 0.001) compared to basal. Hypothalamic explants treated with the combination of α-MSH and Agrp(83–132) (100 nM) resulted in a 179 ± 31% increase in CRH release (p < 0.01) and 130 ± 9% increase in AVP release (p < 0.01) compared to basal, but there was no additive effect. This is the first report that both α-MSH and Agrp(83–132) stimulate the HPA axis. The combination of α-MSH and Agrp(83–132) has no additive effect in vitro and in vivo in male rats. These results suggest that there may be another receptor independent of the known melanocortin receptors at which Agrp is acting.